Everything about Tyrosinase-IN-12
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To judge a number of intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Most important trial aims had been To guage the safety and tolerability of sifalimumab in dermatomyositis or poly